Eisai, Inc. has plans for a new pharmaceutical production and formulation R&D facility for parenteral oncology treatments. Eisai has a number of drugs in development for patients with cancer.
"Oncology is one of Eisai's long-standing therapeutic areas of focus, supporting our human health care mission to increase benefits to patients and their families and satisfy unmet medical needs," said Lonnel Coats, president and chief operating officer, Eisai "Our plans for the new facility in RTP demonstrate Eisai's global commitment to oncology and patients around the world."
The new $90 million, 65,000-sq.-ft. facility will encompass aseptic processing suites, laboratories and other support functions. A separate $15 million central utilities building is also planned to supply power, steam, chilled water and compressed air to the existing operations and the new parenteral facility. Groundbreaking is expected in the fall and completion is anticipated in three years with operations beginning in 2009. The new facilities will lead to 59 new jobs during the next three years and a total of 84 new jobs during the next five years.